Latest Breaking News On - Age touts strong launch for postpartum depression drug zurzuvae - Page 1 : comparemela.com

Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.

United statesBarry greeneSage therapeuticAge touts strong launch for postpartum depression drug zurzuvae